Product Description
OncoC4 is developing AI-061. It is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. Both CTLA-4 and PD-1 are known targets for immunotherapy. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT05858736)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: OncoC4
Company Location: Eastern America
Company Founding Year: 2020
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Adenocarcinoma|Anus Cancer|Bile Duct Cancer|Bladder Cancer|Cervical Cancer|Colorectal Cancer|Endometrial Cancer|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Hepatocellular Carcinoma|Melanoma|Non-Small-Cell Lung Cancer|Peritoneal Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Uterine Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05858736 |
PRESERVE-009 | P1 |
Active, not recruiting |
Colorectal Cancer|Esophageal Cancer|Fallopian Tube Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Endometrial Cancer|Bladder Cancer|Peritoneal Cancer|Bile Duct Cancer|Melanoma|Hepatocellular Carcinoma|Adenocarcinoma|Head and Neck Cancer|Cervical Cancer|Anus Cancer|Uterine Cancer |
2026-07-31 |
50% |
2026-04-10 |
Primary Completion Date|Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|